晚期肠癌靶向治疗进展徐瑞华教授课件.pptVIP

晚期肠癌靶向治疗进展;主要内容;;Phase III CRYSTAL study: Study design;1.0;Independent assessment of response;KRAS analysis: Objective and methodology;KRAS evaluable population;Relating KRAS status to efficacyPrimary endpoint: PFS – KRAS wild-type;Relating KRAS status to efficacyPrimary endpoint: PFS – KRAS mutant;Relating KRAS status to efficacy: PFS;Relating KRAS status to efficacySecondary endpoint: Response;Relating KRAS status to outcome:Most common grade 3/4 adverse events;Conclusions: CRYSTAL study;OPUS: Study design ;KRAS evaluable population;KRAS wild-type: n=134 (58%) ;Relating KRAS status to ef